Immune cell therapy shows promise for Tough-to-Treat lymphoma
NCT ID NCT04673617
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tested a new therapy called AB-101, made from natural killer (NK) cells, in 45 people with B-cell non-Hodgkin lymphoma that had come back or stopped responding to treatment. The study looked at AB-101 alone or combined with other drugs like rituximab or chemotherapy. The goal was to check safety and see if the treatment could shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AB-101 (natural killer cell therapy)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with hard-to-treat B-cell non-Hodgkin lymphoma that has not responded to standard therapies.
- What could go wrong
- This is an early-phase trial with only 45 participants, so results may not apply to all patients. The therapy may cause side effects or fail to show meaningful anti-cancer activity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Artiva Clinical Trial Site
Birmingham, Alabama, 35249, United States
-
Artiva Clinical Trial Site
Tucson, Arizona, 85719, United States
-
Artiva Clinical Trial Site
Orange, California, 92868, United States
-
Artiva Clinical Trial Site
San Diego, California, 92093, United States
-
Artiva Clinical Trial Site
Gainesville, Florida, 32608, United States
-
Artiva Clinical Trial Site
Atlanta, Georgia, 30342, United States
-
Artiva Clinical Trial Site
Chicago, Illinois, 60612, United States
-
Artiva Clinical Trial Site
Iowa City, Iowa, 52242, United States
-
Artiva Clinical Trial Site
Wichita, Kansas, 67214, United States
-
Artiva Clinical Trial Site
Louisville, Kentucky, 40241, United States
-
Artiva Clinical Trial Site
Detroit, Michigan, 48201, United States
-
Artiva Clinical Trial Site
Lake Success, New York, 11042, United States
-
Artiva Clinical Trial Site
New York, New York, 11021, United States
-
Artiva Clinical Trial Site
Columbus, Ohio, 43214, United States
-
Artiva Clinical Trial Site
Portland, Oregon, 97239, United States
-
Artiva Clinical Trial Site
Philadelphia, Pennsylvania, 19107, United States
-
Artiva Clinical Trial Site
Philadelphia, Pennsylvania, 19111, United States
-
Artiva Clinical Trial Site
Providence, Rhode Island, 02903, United States
-
Artiva Clinical Trial Site
Dallas, Texas, 75246, United States
-
Artiva Clinical Trial Site
Salt Lake City, Utah, 84112, United States
-
Artiva Clinical Trial Site
Richmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a MALT1 blocker tame Hard-to-Treat lymphoma?